Skip to main content
S&P 5007,772.56-0.59%DOW50,999.10-1.01%NASDAQ27,395.44-0.74%BTC$83,082.00-3.52%ETH$2,562.06-5.45%GOLD$4,125.20-1.48%OIL$89.87+0.48%
Smart Investors Daily
SID Premium
UP

NASDAQ · UPB

Upstream Bio, Inc.

Healthcare · Biotechnology

$4.59

Up+$0.03 (+0.65%)

Updated Oct 7, 2026, 2:38 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.48B
P/E ratio
-14.14
Dividend yield
0.00%
52-week range
$4.67 – $10.67
Volume
1.06M
Avg. volume
437.05K

Price performance · UPB

UPB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

UPB closed at $4.59 after 21 trading sessions, down 25.85% for the selected period.

Last close
$4.59
Period change
-25.85%
Period low
$4.59
Period high
$6.19
Daily close
View OHLC price history
UPB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$4.84$4.865$4.53$4.591.06M
Oct 5, 2026$5.07$5.10$4.665$4.851.01M
Oct 2, 2026$5.12$5.21$4.86$5.04956.52K
Oct 1, 2026$5.25$5.345$4.98$5.04832.38K
Sep 30, 2026$5.23$5.455$5.145$5.27851.22K
Sep 29, 2026$5.28$5.305$4.99$5.19784.21K
Sep 28, 2026$5.34$5.385$5.12$5.30615.4K
Sep 25, 2026$5.20$5.39$5.07$5.36429.21K
Sep 24, 2026$5.19$5.20$5.045$5.17566.58K
Sep 23, 2026$5.48$5.49$4.985$5.19552.99K
Sep 22, 2026$5.44$5.56$5.38$5.49360.53K
Sep 21, 2026$5.42$5.44$5.27$5.365364.04K
Sep 18, 2026$5.32$5.41$5.21$5.341M
Sep 17, 2026$5.44$5.48$5.235$5.31533.87K
Sep 16, 2026$5.49$5.54$5.27$5.33497.24K
Sep 15, 2026$5.81$5.81$5.455$5.48421.27K
Sep 14, 2026$5.75$5.87$5.70$5.81491.02K
Sep 11, 2026$5.84$5.84$5.65$5.73501.31K
Sep 10, 2026$5.86$5.86$5.67$5.75562.41K
Sep 9, 2026$6.14$6.20$5.77$5.96726.24K
Sep 8, 2026$6.01$6.21$5.77$6.19952.24K

Latest UPB news

The latest Smart Investors Daily articles mentioning UPB.

Stock researchCompany · Overview

UPB research

Overview

Company profile and research snapshot.

Company profile

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$47.00
Implied upside
—
Analysts
—
UPB recent ratings
DateFirmRatingTarget
Sep 2, 2026HC Wainwright & Co.Buy—
Aug 14, 2026JP MorganNeutral—
Aug 12, 2026Truist SecuritiesBuy—
Jun 12, 2026JP MorganNeutral—
Jun 3, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO) with every 12-week dosing – – The Company remains on track to initiate Phase 3 trials in severe asthma and CRSwNP in Q1 2027, designed to deliver best-in-class efficacy in both indications by evaluating a 400 mg quarterly regimen of verekitug in broad patient populat

Yahoo · Sep 1, 2026

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – – The Company’s Phase 3 strategy is designed to deliver best-in-class efficacy across both indications by evaluating a high-dose, quarterly regimen of verekitug in broad patient populations – – The Company remains on track to initiate both Phase 3 trials in Q1 2027 – WALTHAM, Mass., Sept. 0

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By